← Back to Search

Virus Therapy

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Phase 2 & 3
Waitlist Available
Research Sponsored by CytoDyn, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests regular injections of PRO 140 to maintain low HIV levels in patients whose virus is already well-controlled. The drug works by blocking a receptor that HIV uses to infect cells. PRO 140 has been studied for its strong antiviral activity against certain types of HIV.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: PRO 140 700 mgExperimental Treatment1 Intervention
PRO 140 700mg weekly SQ injection.
Group II: PRO 140 525 mgExperimental Treatment1 Intervention
PRO 140 525mg weekly SQ injection.
Group III: PRO 140 350 mgExperimental Treatment1 Intervention
PRO 140 350mg weekly SQ injection.

Find a Location

Who is running the clinical trial?

CytoDyn, Inc.Lead Sponsor
24 Previous Clinical Trials
2,562 Total Patients Enrolled
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top